Compare VRTX & LMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | LMT |
|---|---|---|
| Founded | 1989 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Military/Government/Technical |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 127.4B |
| IPO Year | 2007 | 1995 |
| Metric | VRTX | LMT |
|---|---|---|
| Price | $517.10 | $566.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 24 |
| Target Price | $595.36 | ★ $660.86 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 11-02-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 2.52% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | 10.90 | ★ 22.36 |
| Revenue | $2,488,652,000.00 | ★ $75,048,000,000.00 |
| Revenue This Year | $10.46 | $8.48 |
| Revenue Next Year | $10.53 | $7.03 |
| P/E Ratio | $47.77 | ★ $25.59 |
| Revenue Growth | ★ 46.20 | 5.64 |
| 52 Week Low | $412.27 | $437.25 |
| 52 Week High | $568.67 | $692.00 |
| Indicator | VRTX | LMT |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 43.84 |
| Support Level | $493.75 | $561.85 |
| Resistance Level | $536.58 | $608.67 |
| Average True Range (ATR) | 15.90 | 17.23 |
| MACD | -3.73 | -6.93 |
| Stochastic Oscillator | 4.74 | 4.86 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.